Results 221 to 230 of about 10,448 (268)
Some of the next articles are maybe not open access.
Sildenafil citrate-Associated priapism
Urology, 2000We report the first case of priapism associated with the use of sildenafil citrate. The patient was a 28-year-old man with mild erectile dysfunction after penile trauma who self-treated with a 100-mg dose of sildenafil citrate, resulting in low-flow priapism. After aspiration and intracorporal injection of alpha-agonists, the priapism resolved.
Roger L. Sur, Christopher J. Kane
openaire +2 more sources
Sildenafil citrate: A therapeutic update
Clinical Therapeutics, 2001Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction. Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions.This paper reviews recent studies of the efficacy ...
Eric G. Boyce, Elena M. Umland
openaire +3 more sources
Effects of Testosterone Replacement on Response to Sildenafil Citrate
Annals of Internal Medicine, 2013Comment in In response. Effects of testosterone replacement on response to sildenafil citrate. [Ann Intern Med. 2013] In response. Effects of testosterone replacement on response to sildenafil citrate.Spitzer M, Basaria S, Travison TG, Bhasin S. Ann Intern Med. 2013 Apr 2; 158(7):570-1.
Aversa A +3 more
+11 more sources
Physicochemical Properties of Sildenafil Citrate (Viagra) and Sildenafil Base
Journal of Pharmaceutical Sciences, 2003Sildenafil citrate (Viagra) [I] and sildenafil base [II] are easily and unequivocally characterized by a set of physicochemical methods that include X-ray diffractometry, infrared spectroscopy, and thermal analysis. Monoclinic lattice constants: [I]: a = 26.98 A; b = 11.95 A; c = 16.68 A; beta = 106.97 degrees. [II]: a = 8.66 A; b = 34.27 A; c = 8.93 A;
Melnikov, P. +4 more
openaire +4 more sources
Overall cardiovascular profile of sildenafil citrate
The American Journal of Cardiology, 1999Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. During sexual stimulation, the cavernous nerves release nitric oxide (NO), which induces cyclic guanosine monophosphate (cGMP) formation and smooth muscle relaxation in the corpus cavernosum ...
Dale B. Glasser +3 more
openaire +3 more sources
Intensive and Critical Care Nursing, 1999
Sildenafil is the first of a series of orally active treatments for MED which has resulted in unprecedented demand for treatment and potentially high cost to the NHS. Further oral therapies are likely to follow in the next year or so. In clinical trials, sildenafil produced an erection (sufficient to achieve intercourse) lasting up to 4 h on around 70%
openaire +3 more sources
Sildenafil is the first of a series of orally active treatments for MED which has resulted in unprecedented demand for treatment and potentially high cost to the NHS. Further oral therapies are likely to follow in the next year or so. In clinical trials, sildenafil produced an erection (sufficient to achieve intercourse) lasting up to 4 h on around 70%
openaire +3 more sources
Effects of Sildenafil Citrate on Defibrillation Efficacy
Journal of Cardiovascular Electrophysiology, 2006Introduction: Although fatal arrhythmia and sudden death have been reported in patients taking sildenafil citrate, its effect on defibrillation efficacy has not been investigated. The aim of this study was to test the hypothesis that sildenafil citrate increases the shock strength required to successfully defibrillate during ventricular fibrillation ...
Krekwit Shinlapawittayatorn +3 more
openaire +3 more sources
Sildenafil citrate (Viagra(R))
Drugs of Today, 2000Sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type V (PDE V), initially designated as compound 92-480-10 by Pfizer, was studied in the late 1980s as an antianginal. An unexpected side effect of the early clinical investigations was improved erectile function among the men studied.
openaire +3 more sources
Effects of sildenafil citrate on human hemodynamics
The American Journal of Cardiology, 1999Nitric oxide (NO) induces the formation of intracellular cyclic guanosine monophosphate (cGMP) by guanylate cyclase. Sildenafil, which selectively inhibits phosphodiesterase type 5 (PDE5) found predominantly in the corpora cavernosa of the penis, effectively blocks the degradation of cGMP and enhances erectile function in men with erectile dysfunction.
Jackson Neville Colin +3 more
openaire +3 more sources
Sildenafil citrate for the treatment of pulmonary hypertension
Drugs of Today, 2006Pulmonary arterial hypertension is a progressive disease that has a high rate of mortality. For these reasons, early treatment is essential. Treatment choices for pulmonary arterial hypertension are limited by drug tolerability, drug cost and inconvenience associated with administration techniques and dosing schedules.
Sandra L. Hrometz, Kelly M. Shields
openaire +3 more sources